Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabien Rollot

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 2019
Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric studyJonathan Ciron, Alvaro Cobo-Calvo, Bertrand Audoin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Neurology|April 27, 2018
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR studyAlvaro Cobo-Calvo, Anne Ruiz, Elisabeth Maillart, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
Advances in Therapy|February 19, 2025
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in FranceJérôme de Sèze, Pierre Labauge, Roland Liblau, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
Neurology|July 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple SclerosisAntoine Gavoille, Emmanuelle Leray, Romain Marignier, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 2019
Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric studyJonathan Ciron, Alvaro Cobo-Calvo, Bertrand Audoin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Neurology|April 27, 2018
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR studyAlvaro Cobo-Calvo, Anne Ruiz, Elisabeth Maillart, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2025
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French populationElisabeth Maillart, Fabien Rollot, Emmanuelle Leray, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
Advances in Therapy|February 19, 2025
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in FranceJérôme de Sèze, Pierre Labauge, Roland Liblau, et al.
JAMA Network Open|October 11, 2021
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated SyndromeChristine Lebrun-Frénay, Fabien Rollot, Lydiane Mondot, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
Neurology|July 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple SclerosisAntoine Gavoille, Emmanuelle Leray, Romain Marignier, et al.
Pageof 5